<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.napwa.org.au" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>atazanavir</title>
 <link>http://www.napwa.org.au/articles-by-tx/21</link>
 <description>Embedded view for the TXinfo ctype</description>
 <language>en-au</language>
<item>
 <title>Treatments news from the IAS Conference</title>
 <link>http://www.napwa.org.au/pl/2009/09/treatments-news-from-the-ias-conference</link>
 <description> &lt;p&gt;A roundup of HIV treatments developments from the IAS Conference in Cape Town.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2009/09/treatments-news-from-the-ias-conference&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/abacavir">abacavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nnrtis/nevirapine">nevirapine</category>
 <category domain="http://www.napwa.org.au/living-with-hiv/positive-women/pregnancy-and-childbirth">pregnancy and childbirth</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/integrase-inhibitors/experimental-treatments">raltegravir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/tests/resistance-tests">resistance tests</category>
 <pubDate>Wed, 19 Aug 2009 18:52:42 -0700</pubDate>
 <dc:creator />
 <guid isPermaLink="false">1793 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>HAART on the heart</title>
 <link>http://www.napwa.org.au/pl/2009/06/haart-on-the-heart</link>
 <description> &lt;p&gt;Starting Highly Active &lt;a class=&quot;glossary-term&quot; href=&quot;/glossary/term/122&quot;&gt;&lt;span&gt;Antiretroviral&lt;/span&gt;&lt;/a&gt;&lt;span class=&quot;hovertip&quot;&gt;A medication or other substance which is active against retroviruses such as HIV.&lt;/span&gt; Therapy can improve some of the things that lead to heart problems but not all of them, a recent study has revealed. Arteries which are already thickened or hardened do not improve on treatment. Metabolic complications, including increases in blood levels of lipids, are common in people on treatment and can also contribute to this condition.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2009/06/haart-on-the-heart&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/abacavir">abacavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/heart-disease">heart disease</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/lopinavir">lopinavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/ritonavir">ritonavir</category>
 <pubDate>Thu, 04 Jun 2009 23:20:40 -0700</pubDate>
 <dc:creator>Jill Sergeant</dc:creator>
 <guid isPermaLink="false">1587 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>Atazanavir switch doesn’t reduce belly fat</title>
 <link>http://www.napwa.org.au/pl/2008/09/atazanavir-switch-doesn%E2%80%99t-reduce-belly-fat</link>
 <description> &lt;p&gt;In a disappointing finding from the REAL study, little difference was shown in visceral fat levels from those who shifted to atazanavir/ritonavir versus those remaining on their existing boosted &lt;a class=&quot;glossary-term&quot; href=&quot;/glossary/term/108&quot;&gt;&lt;span&gt;protease inhibitor&lt;/span&gt;&lt;/a&gt;&lt;span class=&quot;hovertip&quot;&gt;A type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate.&lt;/span&gt;.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2008/09/atazanavir-switch-doesn%E2%80%99t-reduce-belly-fat&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/lipodystrophy-and-lipoatrophy">Lipodystrophy and lipoatrophy</category>
 <pubDate>Tue, 23 Sep 2008 20:24:44 -0700</pubDate>
 <dc:creator>David Menadue</dc:creator>
 <guid isPermaLink="false">870 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>Rocky Mountain CROI</title>
 <link>http://www.napwa.org.au/pl/2006/04/rocky-mountain-croi</link>
 <description> &lt;p&gt;The 13th annual Conference on Retroviruses and Opportunistic Infections (&lt;span class=&quot;caps&quot;&gt;CROI&lt;/span&gt;) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the &lt;span class=&quot;caps&quot;&gt;SMART&lt;/span&gt; study, but as usual, this important conference produced a great deal more than a single story.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2006/04/rocky-mountain-croi&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/protease-inhibitors/experimental-treatments-0">darunavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/integrase-inhibitors/experimental-treatment-0">elvitegravir (GS-9137)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/nnrtis/experimental-treatments/etravirine-t">etravirine (TMC-125)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/heart-disease">heart disease</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/hepatitis-c">hepatitis C</category>
 <category domain="http://www.napwa.org.au/living-with-hiv/defeating-hiv/sex-and-relationships/hiv-prevention/pre-exposure-prophylaxis-prep">Pre-exposure prophylaxis (PrEP)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/integrase-inhibitors/experimental-treatments">raltegravir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/multi-class-formulations/truvada">Truvada</category>
 <enclosure url="http://www.napwa.org.au/image/view/1306/preview" length="34082" type="image/jpeg" />
 <pubDate>Wed, 26 Apr 2006 07:08:00 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">543 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>Much more than a junket</title>
 <link>http://www.napwa.org.au/pl/2005/10/much-more-than-a-junket</link>
 <description> &lt;p&gt;A report from the 3rd IAS Conference on HIV Pathogenesis and Treatment, held in Rio de Janiero in July.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2005/10/much-more-than-a-junket&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/taxonomy/term/346">conference reports</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/protease-inhibitors/experimental-treatments-0">darunavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/entry-inhibitors">entry and fusion inhibitors</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/lopinavir">lopinavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/experimental-treatments/attachment-inhibitor">maraviroc</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/experimental-treatments/entry-inhibitors/pr">PRO-542</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/ritonavir">ritonavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/protease-inhibitors/experimental-treatments">tipranavir</category>
 <category domain="http://www.napwa.org.au/taxonomy/term/358">Brazil</category>
 <enclosure url="http://www.napwa.org.au/image/view/808/preview" length="14440" type="image/jpeg" />
 <pubDate>Wed, 12 Oct 2005 07:08:03 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">429 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>Triple treat</title>
 <link>http://www.napwa.org.au/pl/2004/10/triple-treat</link>
 <description> &lt;p&gt;The &lt;a class=&quot;glossary-term&quot; href=&quot;/glossary/term/121&quot;&gt;&lt;span&gt;Pharmaceutical Benefits Scheme&lt;/span&gt;&lt;/a&gt;&lt;span class=&quot;hovertip&quot;&gt;[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.&lt;/span&gt; has recently added three new &lt;a class=&quot;glossary-term&quot; href=&quot;/glossary/term/122&quot;&gt;&lt;span&gt;antiretrovirals&lt;/span&gt;&lt;/a&gt;&lt;span class=&quot;hovertip&quot;&gt;A medication or other substance which is active against retroviruses such as HIV.&lt;/span&gt;, to become available on prescription in December. PAUL KIDD takes a look at the newest weapons in the anti-HIV armoury.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2004/10/triple-treat&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/entry-inhibitors/t-20">enfuvirtide (T-20)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/fosamprenavir">fosamprenavir/amprenavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments">HIV treatments</category>
 <category domain="http://www.napwa.org.au/treating-hiv/accessing-hiv-care-and-treatment/pharmaceutical-benefits-scheme">Pharmaceutical Benefits Scheme</category>
 <enclosure url="http://www.napwa.org.au/image/view/841/preview" length="14797" type="image/jpeg" />
 <pubDate>Thu, 14 Oct 2004 16:00:51 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">63 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>Bangkok AIDS Conference: Small steps</title>
 <link>http://www.napwa.org.au/pl/2004/08/bangkok-aids-conference-small-steps</link>
 <description> &lt;p&gt;There isn&amp;rsquo;t a lot of Earth-shattering news to report from Bangkok, but as always there were numerous small developments. As PAUL KIDD explains, some of these small steps could develop into giant leaps.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2004/08/bangkok-aids-conference-small-steps&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/maturation-inhibitors/experimental-treatment">bevirimat (MPC-4326, PA-457)</category>
 <category domain="http://www.napwa.org.au/taxonomy/term/346">conference reports</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/entry-inhibitors/t-20">enfuvirtide (T-20)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/fosamprenavir">fosamprenavir/amprenavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments">HIV treatments</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/lipodystrophy-and-lipoatrophy">Lipodystrophy and lipoatrophy</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/maturation-inhibitors">maturation inhibitors</category>
 <category domain="http://www.napwa.org.au/taxonomy/term/235">Thailand</category>
 <enclosure url="http://www.napwa.org.au/image/view/848/preview" length="39053" type="image/jpeg" />
 <pubDate>Sat, 14 Aug 2004 13:00:22 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">83 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>The power of one</title>
 <link>http://www.napwa.org.au/pl/2003/12/the-power-of-one</link>
 <description> &lt;p&gt;We all want simpler treatment regimens with fewer side effects and no meal restrictions, right? Well how does once-a-day treatment sound? As &lt;span class=&quot;caps&quot;&gt;PAUL&lt;/span&gt; &lt;span class=&quot;caps&quot;&gt;KIDD&lt;/span&gt; reports, it may be closer than you think.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2003/12/the-power-of-one&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/ddi">didanosine (ddI)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nnrtis/efavirenz">efavirenz</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/ftc">emtricitabine (FTC)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/fosamprenavir">fosamprenavir/amprenavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments">HIV treatments</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/3tc">lamivudine (3TC)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nnrtis/nevirapine">nevirapine</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/experimental-treatments/entry-inhibitors/pr">PRO-542</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/ritonavir">ritonavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/saquinavir">saquinavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/d4t">stavudine (d4T)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/ntrtis/tenofovir">tenofovir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nrtis/azt">zidovudine (AZT)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/multi-class-formulations">multi-class formulations</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/experimental-treatments">experimental treatments</category>
 <enclosure url="http://www.napwa.org.au/image/view/1263/preview" length="9870" type="image/jpeg" />
 <pubDate>Sun, 14 Dec 2003 12:00:21 -0800</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">132 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>&#039;The greatest health crisis in human history&#039;</title>
 <link>http://www.napwa.org.au/pl/2003/08/the-greatest-health-crisis-in-human-history</link>
 <description> &lt;p&gt;The major international &lt;span class=&quot;caps&quot;&gt;AIDS&lt;/span&gt; conference for 2003 has ended with encouraging signs of growing international commitment to fight &lt;span class=&quot;caps&quot;&gt;AIDS&lt;/span&gt; in the developing world, and with several promising medical developments.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2003/08/the-greatest-health-crisis-in-human-history&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/diarrhoea">diarrhoea</category>
 <category domain="http://www.napwa.org.au/understanding-hiv-treatments/treating-hiv/salvage-therapy/understanding-hiv-treatments/drug-resista">drug resistance</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/heart-disease">heart disease</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/hepatitis-c">hepatitis C</category>
 <category domain="http://www.napwa.org.au/treating-hiv/symptoms-illnesses-and-opportunistic-infections/lipodystrophy-and-lipoatrophy">Lipodystrophy and lipoatrophy</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors">protease inhibitors</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/ntrtis/tenofovir">tenofovir</category>
 <category domain="http://www.napwa.org.au/defeating-hiv/the-global-hiv-epidemic">The global HIV epidemic</category>
 <category domain="http://www.napwa.org.au/treating-hiv/treating-hiv/hiv-treatments/hiv-treatments/protease-inhibitors/experimental-treatments">tipranavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/treatment-interruption">treatment interruption</category>
 <enclosure url="http://www.napwa.org.au/image/view/1278/preview" length="32268" type="image/jpeg" />
 <pubDate>Thu, 31 Jul 2003 07:00:22 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">310 at http://www.napwa.org.au</guid>
</item>
<item>
 <title>News and treatments briefs</title>
 <link>http://www.napwa.org.au/pl/2003/06/news-and-treatments-briefs</link>
 <description> &lt;p&gt;HIV-related news in brief from the June-July 2003 edition of &lt;cite&gt;Positive Living&lt;/cite&gt;.&lt;/p&gt;
 &lt;p&gt;&lt;a href=&quot;http://www.napwa.org.au/pl/2003/06/news-and-treatments-briefs&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/protease-inhibitors/atazanavir">atazanavir</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nnrtis/efavirenz">efavirenz</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/complementary-and-alternative-therapies/medical-cannabis">medical cannabis</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/nnrtis/nevirapine">nevirapine</category>
 <category domain="http://www.napwa.org.au/defeating-hiv/hiv-prevention/superinfection/reinfection">superinfection/reinfection</category>
 <category domain="http://www.napwa.org.au/treating-hiv/tests/therapeutic-drug-monitoring-tdm">therapeutic drug monitoring (TDM)</category>
 <category domain="http://www.napwa.org.au/treating-hiv/hiv-treatments/treatment-interruption">treatment interruption</category>
 <pubDate>Sat, 31 May 2003 07:00:48 -0700</pubDate>
 <dc:creator>Paul Kidd</dc:creator>
 <guid isPermaLink="false">341 at http://www.napwa.org.au</guid>
</item>
</channel>
</rss>
